{
    "nct_id": "NCT03363373",
    "age": "Adults",
    "cancer_center_accrual_goal_upper": 0,
    "curated_on": "2017-12-06",
    "study_start_date": "2018-04-03",
    "study_completion_date": "",
    "data_table4": "Interventional",
    "drug_list": {
        "drug": [
            {
                "drug_name": "Biological: GM-CSF + Naxitamab"
            }
        ]
    },
    "long_title": "A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow",
    "last_updated": "2025-08-17",
    "management_group_list": {
        "management_group": [
            {
                "is_primary": "Y",
                "management_group_name": "Group1"
            }
        ]
    },
    "oncology_group_list": {
        "oncology_group": [
            {
                "group_name": "Group1",
                "is_primary": "N"
            }
        ]
    },
    "phase": "PHASE2",
    "principal_investigator": "NA",
    "principal_investigator_institution": "Y-mAbs Therapeutics",
    "program_area_list": {
        "program_area": [
            {
                "is_primary": "Y",
                "program_area_name": "Program1"
            }
        ]
    },
    "protocol_id": 0,
    "protocol_ids": [],
    "protocol_no": "",
    "protocol_target_accrual": 122,
    "protocol_type": "INTERVENTIONAL",
    "prior_treatment_requirements": [
        "Inclusion Criteria:",
        "* Diagnosis of neuroblastoma as defined per International Neuroblastoma Response Criteria",
        "* High-risk neuroblastoma patients with either primary refractory disease or incomplete response to salvage treatment (in both cases including stable disease, minor response and partial response) evaluable in bone and/or bone marrow.",
        "* Life expectancy \u2265 6 months",
        "Exclude - Exclusion Criteria:",
        "Exclude - * Any systemic anti-cancer therapy, including chemotherapy or immunotherapy, within 3 weeks before 1st dose of GM-CSF",
        "Exclude - * Evaluable neuroblastoma outside bone and bone marrow",
        "Exclude - * Existing major organ dysfunction \\> Grade 2, with the exception of hearing loss, hematological status, kidney and liver function",
        "Exclude - * Active life-threatening infection"
    ],
    "short_title": "Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow",
    "site_list": {
        "site": []
    },
    "sponsor_list": {
        "sponsor": [
            {
                "is_principal_sponsor": "Y",
                "sponsor_name": "Y-mAbs Therapeutics",
                "sponsor_protocol_no": "",
                "sponsor_roles": "sponsor"
            }
        ]
    },
    "staff_list": {
        "protocol_staff": []
    },
    "status": "open to accrual",
    "summary": "Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first dose.\n\nNaxitamab, also known as hu3F8 is a humanised monoclonal antibody targeting GD2",
    "treatment_list": {
        "step": [
            {
                "step_internal_id": 111,
                "step_code": "1",
                "step_type": "Registration",
                "arm": [
                    {
                        "arm_code": "GM-CSF + Naxitamab",
                        "arm_internal_id": 0,
                        "arm_description": "Each investigational cycle is started with 5 days of GM-CSF administered at 250 \u00b5g/m2/day in advance of the start of Naxitamab administration. GM-CSF is thereafter administered at 500 \u00b5g/m2/day on days 1 to 5. As standard treatment, Naxitamab is administered at 3 mg/kg/day on days 1, 3, and 5 totalling 9 mg/kg per cycle. Treatment cycles are repeated every 4 weeks until CR or PR followed by 5 additional cycles every 4 weeks (\u00b11 week). Subsequent cycles are repeated every 8 weeks (\u00b12 weeks) through 101 weeks from first infusion at the discretion of the investigator. After end of treatment patients will enter a long-term follow up for up to 3 years after end of treatment visit.",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Biological: GM-CSF + Naxitamab",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            }
                        ]
                    }
                ],
                "match": [
                    {
                        "and": [
                            {
                                "or": [
                                    {
                                        "clinical": {
                                            "oncotree_primary_diagnosis": "Ganglioneuroblastoma"
                                        }
                                    },
                                    {
                                        "clinical": {
                                            "oncotree_primary_diagnosis": "Neuroblastoma"
                                        }
                                    }
                                ]
                            },
                            {
                                "clinical": {
                                    "disease_status": [
                                        "Refractory"
                                    ]
                                }
                            }
                        ]
                    }
                ]
            }
        ]
    }
}